HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced plans to release its fourth quarter and full year 2022 financial results on March 15, 2023, before the market opens. The company will host a live conference call at 8:30 AM ET to discuss these results and provide a corporate update. HOOKIPA specializes in developing immunotherapeutics based on its proprietary arenavirus platform, targeting cancers and viral diseases such as HBV and HIV. The company collaborates with notable partners including Roche and Gilead. For access details, participants can find the webcast link on HOOKIPA's investor relations page.

Positive

• Upcoming financial results expected to provide insights on company performance.
• Investments in immunotherapies targeting significant health issues, including HPV-related cancers and viral diseases.
• Collaboration with major pharmaceutical companies like Roche and Gilead may enhance research and development capabilities.

Negative

• None.

NEW YORK and VIENNA, March 08, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2022 financial results before the market opens on Wednesday, March 15, 2023. The Company will host a live conference call and webcast at 8:30 AM ET to discuss its financial results and provide a corporate update.

Conference Call & Webcast:
Date:			March 15, 2023
Time:			8:30 AM ET
USA Dial In:			+1-800-715-9871
UK Dial In:			0800-260-6466
Austria Dial In:			+43 800-070-441
Conference ID:			7669853
Webcast:			Link

The webcast and the presentation will also be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events.

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed programs. HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:
Media			Investors
Instinctif Partners			Matt Beck
hookipa@instinctif.com			Executive Director - Investor Relations
+44 (0)20 7457 2020			matthew.beck@hookipapharma.com
			+1 917 209 6886

 

FAQ

When will HOOKIPA release its fourth quarter financial results?

HOOKIPA will release its fourth quarter financial results on March 15, 2023, before the market opens.

What time is the HOOKIPA conference call on March 15, 2023?

The HOOKIPA conference call is scheduled for 8:30 AM ET on March 15, 2023.

What is HOOKIPA Pharma's focus in drug development?

HOOKIPA Pharma focuses on developing novel immunotherapies based on its proprietary arenavirus platform to treat and prevent serious diseases.

Who are HOOKIPA's collaborators in their drug development?

HOOKIPA collaborates with Roche for cancer therapeutics and Gilead to develop functional cures for HBV and HIV.